Jump to content

KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors


In The News

Recommended Posts

Archived

This topic is now archived and is closed to further replies.



×
×
  • Create New...